Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.55 |
| ▸ | HRH2 | P25021 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7556302 | 1.00 | KMT2A (0.62) | KMT2AMAPK1PABPC1HRH2HRH1 | |
| SCHEMBL6161351 | 0.90 | KMT2A (0.57) | KMT2AMAPK1PABPC1HRH2HRH1 | |
| SCHEMBL5891895 | 0.88 | KMT2A (0.54) | KMT2AMAPK1PABPC1HRH2HRH1 | |
| SCHEMBL7598387 | 0.83 | CHRM1 (0.52) | KMT2AMAPK1PABPC1HRH2HRH1 | |
| SCHEMBL606221 | 0.80 | ACE (0.61) | SCN9AACECYP3A4 | |
| SCHEMBL479035 | 0.80 | ACE (0.61) | SCN9AACECYP3A4 | |
| SCHEMBL479037 | 0.80 | ACE (0.61) | SCN9AACECYP3A4 | |
| SCHEMBL30655780 | 0.80 | ACE (0.61) | SCN9AACECYP3A4 | |
| SCHEMBL29401567 | 0.80 | ACE (0.61) | SCN9AACECYP3A4 | |
| SCHEMBL30547269 | 0.80 | ACE (0.61) | SCN9AACECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082262-A1 | Substituted bicyclic compounds for treating multidrug resistance | PROCTER & GAMBLE COMPANY, THE | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082262-A1 | Substituted bicyclic compounds for treating multidrug resistance | ABCB1, ABCC1, ABCB11 | KMT2A 3111/4885MAPK1 4824/4885PABPC1 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.